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Abstract
The azurophilic granules of human neutrophils contain four a-defensins called human neutrophil peptides (HNPs 1–4). HNPs
are tridisulfide-linked antimicrobial peptides involved in the intracellular killing of organisms phagocytosed by neutrophils.
The peptides are produced as inactive precursors (proHNPs) which are processed to active microbicides by as yet
unidentified convertases. ProHNP1 was expressed in E. coli and the affinity-purified propeptide isolated as two species, one
containing mature HNP1 sequence with native disulfide linkages (‘‘folded proHNP1’’) and the other containing non-native
disulfide linked proHNP1 conformers (misfolded proHNP1). Native HNP1, liberated by CNBr treatment of folded proHNP1,
was microbicidal against Staphylococcus aureus, but the peptide derived from misfolded proHNP1 was inactive. We
hypothesized that neutrophil elastase (NE), proteinase 3 (PR3) or cathepsin G (CG), serine proteases that co-localize with
HNPs in azurophil granules, are proHNP1 activating convertases. Folded proHNP1 was converted to mature HNP1 by both
NE and PR3, but CG generated an HNP1 variant with an N-terminal dipeptide extension. NE and PR3 cleaved folded
proHNP1 to produce a peptide indistinguishable from native HNP1 purified from neutrophils, and the microbicidal activities
of in vitro derived and natural HNP1 peptides were equivalent. In contrast, misfolded proHNP1 conformers were degraded
extensively under the same conditions. Thus, NE and PR3 possess proHNP1 convertase activity that requires the presence of
the native HNP1 disulfide motif for high fidelity activation of the precursor in vitro.
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Introduction
Antimicrobial peptides (AMPs) produced by animal cells
provide a first line of defense against potentially infectious
microorganisms. In mammals, defensins and cathelicidins are
the primary AMPs expressed in professional phagocytes such as
neutrophils and macrophages [1]. Mammalian defensins comprise
three structural subfamilies termed a-, b- and h-defensins. While
all defensins are arginine rich, tridisulfide containing peptides, they
are distinguished from each other by the presence of unique
disulfide motifs [2]. In addition, h-defensins, which are approx-
imately half the size of a- and b-defensins, are macrocyclic
molecules which have only been isolated from leukocytes of Old
World monkeys (reviewed in [2,3]). Defensins have antimicrobial
activities against diverse microbial targets that include bacteria [4],
fungi [5,6], viruses [7,8,9], and protozoa [10]. Certain a-, b-, and
h-defensins function as regulators of adaptive immune cells and
thus function to modulate inflammation [11,12,13] and bridge
innate and adaptive immunity [14].
In humans, four a-defensins, human neutrophil peptides 1–4
(HNP 1–4), are expressed in neutrophils and monocytes of myeloid
lineage, and a-defensins (HD5 and HD6) are produced primarily
in Paneth cells of the small intestine. In neutrophils, HNP 1–4 are
stored in the cytoplasmic azurophil granules which are mobilized
during phagocytosis resulting in the exposure of ingested
microorganisms to high concentrations of HNPs in the phagolyso-
somes [2]. In the setting of bacteremic sepsis, HNPs also
accumulate in the extracellular compartment [15,16]. Several
studies have demonstrated an extracellular role for myeloid a-
defensins in regulating cellular activities including cell proliferation
[17,18,19], neovascularization [20,21], chemotaxis [22], and
regulation of cytokines [23,24] and signal transduction pathways
[17,19,24,25]. To date, these activities have been attributed to the
mature, folded a-defensin.
Defensins of all three subfamilies are expressed as prepro-
defensins containing an N-terminal signal peptide followed by the
propeptide that contains the prosegment and the folded/oxidized
mature peptide sequence [26]. The prosegment in a- and h-
defensin precursors is ,45 amino acids in length, but that of b-
defensin precursors is typically very short. In a-defensins, studies
suggest that the anionic prosegment interacts with residues present
in the mature peptide to maintain it in an inactive state until it
reaches the correct cellular location, possibly to protect cellular
compartments from peptide-mediated cytotoxic effects [27,28,29].
Processing of the human enteric a-defensin, HD5 occurs
extracellularly and is mediated by trypsin [30], whereas mouse
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metalloprotease 7 (MMP7, matrilysin) [31]. Neutrophil elastase
(NE), an azurophil granule protease, was shown to correctly
process RMAD4, a rhesus macaque neutrophil a-defensin in vitro
[32]. Bovine and human cathelicidins, a distinct class of
antimicrobial peptides, are processed by the azurophil granule
proteases, NE [33] and proteinase 3 (PR3) [34] respectively.
Studies with HL-60 cells, a human acute promyelocytic leukemia
cell line, show that HNPs are biosynthesized and processed to
mature peptides in these cells [35], but the proteases involved in
maturation of human myeloid a-defensins have not been
identified. Because HNPs co-localize to neutrophil granules
containing the serine proteases NE, PR3 and cathepsin G (CG)
[36], we hypothesized that HNP maturation is mediated by one or
more of these proteinases. In this study, recombinant proHNP1
was used as substrate to analyze the human a-defensin convertase
activities of NE, PR3, and CG. The requirement for the native
HNP1 fold was analyzed by assessing the processing of folded and
misfolded preparations of proHNP1. In addition, the antimicro-
bial activity of the resulting HNP-1 peptides was analyzed utilizing
Staphylococcus aureus as the test organism.
Results
Expression and Purification of His6-proHNP1
Recombinant hexa-His-tagged pro-HNP-1 (Fig. 1) was expressed
at approximately 2 mg/L in E. coli cells. The imidazole eluant from
the nickel affinity column (Ni-eluant) contained a major band of
,12 kDa, consistent with the molecular weight of His6-proHNP1
(theory =12647 A.M.U.; Fig. 2A). C18 reversed phase high
performance liquid chromatography (RP-HPLC) of the Ni-eluant
produced two major peaks (A and B; Fig. 2B). On reducing SDS-
tricinePAGE,peaksAandBcontainedthe,12 kDaband(Fig.2C)
and both were detected with anti-His6 antibody confirming the
presence of His6-proHNP1 (Fig. 2D). On AU-PAGE, His6-
proHNP1 present in peak A (proHNP1A) migrated more rapidly
than that contained in peak B (proHNP1B; Fig. 2E), suggesting that
proHNP1A and proHNP1B are differently folded forms of the
recombinant protein. This was confirmed by the finding that DTT-
reduced proHNP1A and proHNP1B co-eluted on RP-HPLC (data
not shown) and by demonstrating that folding of proHNP1B in the
presence of reduced/oxidized glutathione led to the formation of
proHNP1A (Text S1 and Figure S1). Thus, proHNP1A and
proHNP1B contain folded and misfolded His6-proHNP1 respec-
tively. ProHNP1A and proHNP1B-containing fractions were
pooled separately and purified to homogeneity by a second round
of RP-HPLC (Fig. 2F).
HNP1 derived from proHNP1A and proHNP1B
The presence of a Met residue at the junction of the prosegment
and mature peptide in proHNP1 sequence (see Fig. 1) offered a
non-enzymatic approach to generate HNP1 from proHNP1
utilizing cyanogen bromide (CNBr) cleavage [28]. Cleavage of
proHNP1A with CNBr, followed by C18 RP-HPLC, gave rise to a
major peptide product (Fig. 3A) with a mass (Fig. 3B) and HPLC
retention time (Fig. 3C) matching that of natural HNP1. However,
CNBr digestion of proHNP1B generated multiple species (Fig. 3A)
that had masses consistent with oxidized HNP1 (Fig. 3B), but
which eluted later than native HNP1 in RP-HPLC (Fig. 3C). On
AU PAGE, HNP1 derived from proHNP1A comigrated with
natural HNP1. However, HNP1 derived from proHNP1B
migrated more rapidly than the natural standard (Fig. 3D). These
data demonstrate that proHNP1A contained folded HNP1 with
native disulfide linkages but the mature peptide in proHNP1B,
although oxidized, is misfolded and contains non-native disulfide
linkages. In solution, HNP1 exists as a non-covalent dimer [37]
and the dimeric form corresponds to the single band observed in
AU PAGE (Selsted et al., unpublished data). Therefore, it is likely
that the higher mobility of proHNP1B-derived HNP1 (Fig. 3D) is
due to the monomeric state of this conformer.
Microbicidal activities of HNP1 isoforms
To analyze the microbicidal properties of the HNP1 conformers
produced by CNBr cleavage of proHNP1A and proHNP1B, we
tested the respective peptides for killing of S. aureus in vitro. HNP1
derived from proHNP1A had microbicidal activity similar to that
of native HNP1 (Fig. 4). However, HNP1 derived from
proHNP1B was devoid of staphylocidal activity (Fig. 4). Thus,
formation of native disulfide linkages in HNP1 is essential for the
staphylocidal activity of the peptide, and may reflect a further
requirement for dimerization.
Processing of His6-proHNP1 by azurophil granule
proteases
Previous studies have demonstrated that NE, PR3, and CG co-
localize with HNPs in the azurophil granules of neutrophils.
Kamdar et al. demonstrated that NE digestion of proRMAD4,
precursor of rhesus myeloid a-defensin-4 (RMAD4), converted
proRMAD4 to mature RMAD4. However, digestion of pro-
RMAD4 with PR3 and CG generated RMAD4 variants with N-
terminal extensions (Fig. 5D) [32]. To test for the role of these
granule serine proteases in human HNP processing, proHNP1A
was incubated in separate reactions with NE, PR3, or CG, and the
RP-HPLC-purified cleavage products were analyzed by MALDI-
TOF MS and analytical HPLC (Fig. 5 and Table 1). Incubation of
His6-proHNP1withNEorPR3generated peptide productsthatco-
eluted with native HNP1 in RP-HPLC (34.8 min; Fig. 5A, B) and
had monoisotopic masses of 3440.6 and 3441.3 A.M.U. respective-
ly, consistent with the mass of native HNP1 (3439.9 A.M.U.
observed; theory=3439.5 A.M.U.; Table 1). The identities of
HNP1 derivatives were also confirmed by MALDI-TOF MS of
each peptide following reduction and S-carboxyamidomethylation.
In each case reduction and alkylation produced a mass increase of
348 A.M.U., confirming the presence of 6 disulfide-linked cysteine
residues (Table 1). The NE- and PR3-derived peptides also co-
migrated with native HNP1 on AU-gels (Fig. 5C; lanes 1–3). Thus,
NE and PR3 processing of His6-proHNP1 generated a peptide that
was indistinguishable from natural HNP1.
Incubation of His6-proHNP1 with CG did not generate mature
HNP1 but instead a digestion product that eluted from C18 HPLC
later than HNP1 (Fig. 5A) and had a mass of 3685.4 A.M.U. This
mass corresponds to HNP1 with a dipeptidyl (Asn-Met-) amino-
terminal extension, consistent with Lys62QAsn63 cleavage by CG
(Fig. 5D). The CG liberated HNP1 product eluted as a single peak
(Fig.5A),whichwasresolvedinto twospeciesbyhighresolution RP-
HPLC (Alliance analytical HPLC system; Fig. 5B). Peptide in the
second peak corresponded to the mass of Asn-Met-HNP-1 (3685.8
A.M.U.). Peptide in the earlier eluting peak was 3702.0 A.M.U., an
increase of 16.2 A.M.U., corresponding to the sulfoxide derivative
of methionine (theory=16.0 A.M.U.) of Asn-Met-HNP1. Despite
the chromatographic heterogeneity observed, CG-derived Asn-
Met-HNP1 migrated as a single band on AU-PAGE, comigrating
with native HNP1 (Fig. 5C, lanes 4 and 5).
Analysis of Tag sequence effects on proHNP1 processing
Although the junctional sequences recognized by NE, PR3, and
CG in His6-proHNP1 are identical to those in the natural
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proHNP-1 sequence resulting from the hexa-His and DDDDK
tags and spacer sequences might alter protease interactions with
the target. To test this, we produced proHNP1 without the N-
terminal tag by incubating proHNP1A with enterokinase, thereby
releasing the 41-residue tag sequence. This peptide was then
treated with NE, PR3, or CG which liberated peptides with
monoisotopic masses of 3439.7, 3439.7 and 3684.5 A.M.U.,
respectively, products equivalent to those generated from His6-
proHNP1A. Thus the 41-residue N-terminal fusion tag did not
alter the specificity of cleavage of proHNP1A by NE, PR3, or CG.
Protease processing of misfolded His6-proHNP1
NE, PR3, and CG degraded proHNP1B, the misfolded form of
the HNP1 precursor. In contrast to the discrete products
generated by digestion of proHNP1A by the serine proteases
(Fig. 5), NE, PR3, or CG treatment of proHNP1B yielded no
mature HNP1 or HNP1 derivatives in the digestion mixtures
detectable by C18 RP-HPLC or MALDI-TOF MS (data not
shown). These results indicate that the correct fold and disulfide
linkages in proHNP1 are required for processing of the precursor
to mature peptide and to confer resistance to these activating
convertases.
Microbicidal activities of HNP1 products of proHNP1A
processing by NE, PR3 and CG
The functional properties of HNP1 generated by serine protease
processing of proHNP1A were tested in microbicidal assays
against S. aureus. Natural HNP1 and NE, PR3 and CG processed
preparations possessed nearly identical dose-dependent bacteri-
Figure 1. Schematic representation of His6-proHNP1. Top Panel. The 36 amino acid residue N-terminal extension showing the His6-tag from
the pET28a+ vector followed by the enterokinase site and proHNP1 sequence in the His6-proHNP1 construct are shown. The numbers above indicate
the number of amino acid residues in each segment. Bottom Panel. The proHNP1 sequence showing the mature sequence (underlined), the disulfide
linkages between Cys residues, and the Met residue (indicated with an asterisk) at the junction of the pro- and mature sequence. The numbers
indicate the residue number in the preproHNP1 precursor.
doi:10.1371/journal.pone.0032469.g001
Figure 2. Purification of His6-proHNP1 foldamers. A) Ni-column eluant was analyzed by SDS-tricine PAGE and Coomassie stained; arrowhead
indicates the major ,12 kDa recombinant protein in the eluant. B) HPLC chromatogram of Ni-eluant resolved by semi-preparative C18 RP-HPLC
generates two major peaks, A and B. C) HPLC fractions (numbers indicated) shown in panel B were resolved on SDS-tricine gel and stained with
Coomassie blue, (D) analyzed by western blotting using anti-His6-tag antibody, and by (E) Coomassie staining following AU-PAGE. F) His6-proHNP1
containing fractions 36–38 (His6-proHNP1A) and fractions 41–42 (His6-proHNP1B) were pooled and further purified by RP-HPLC on C18 column and
analyzed by Coomassie staining samples resolved on SDS-tricine gel (lane 1 - His6-proHNP1A, lane 2 - His6-proHNP1B).
doi:10.1371/journal.pone.0032469.g002
Processing of proHNP1 by Azurophilic Proteases
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32469cidal activities against this organism (Fig. 6). These data
demonstrate that HNP1 generated by NE and PR3 processing
of proHNP1A is functionally equivalent to native HNP1. Of note,
the Asn-Met-HNP1, produced by CG processing of proHNP1A,
had staphylocidal activity equivalent to that of the fully processed
HNP1 isoform.
Discussion
To study the processing of human myeloid a-defensins, we
established an in vitro assay utilizing recombinant proHNP1.
Approximately 60% of the recombinant His6-proHNP1 was
folded with native disulfide linkages (Fig. 2) and misfolded
propeptide was readily converted to the folded form in buffer
containing urea and reduced/oxidized glutathione (Fig. S1). The
expression of folded and misfolded forms of proHNP1 allowed for
the analysis of the structural requirements for HNP1-mediated
bactericidal activity in vitro. CNBr treatment of folded (proHNP1A)
or misfolded (proHNP1B) precursor generated different HNP1
conformers (Fig. 3). Despite the generation of oxidized peptides
with masses matching that of natural HNP1, only the conformer
Figure 3. HNP1 forms released by CNBr cleavage of His6-proHNP1. HNP1 peptides were generated by CNBr cleavage of folded His6-
proHNP1A and misfolded His6-proHNP1B. A) HNP1 generated by CNBr cleavage of His6-proHNP1B (upper tracing) and His6-proHNP1A (lower tracing)
were resolved by C18 RP-HPLC. Bar indicates fractions containing peptides with molecular weight consistent with that of folded/oxidized HNP1 and
peaks marked with arrows were further purified by HPLC. B) MALDI-TOF MS of CNBr-cleaved HNP1 derived from His6-proHNP1B (upper panel) and
His6-proHNP1A (lower panel). C) Analytical C18 RP-HPLC using the Alliance system of HNP1 generated by CNBr-cleavage of His6-proHNP1B and His6-
proHNP1A compared with neutrophil derived native HNP1. D) AU-PAGE analysis followed by Coomassie staining of 2 mg of each sample shown in
panel C: peak B-derived HNP1 (lane 1), peak A-derived HNP1 (lane 2), native HNP1 (lane 3).
doi:10.1371/journal.pone.0032469.g003
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activity against S. aureus. Processing of proHNP1A by NE or PR3
generated HNP1 peptide identical to natural HNP1, but
proHNP1B was heterogeneous and was degraded by NE, PR3
and CG. These data demonstrate that the native HNP1 fold is
necessary for proteolytic stability and accurate processing of the
HNP1 propeptide by the three azurophil granule serine proteases
investigated.
The requirement for the native HNP1 fold for microbicidal
activity is consistent with a previous report demonstrating that an
all Cys-to-Ala analog of HNP1 was nearly 10-fold less potent in
bactericidal assays than the native peptide [38]. Similarly,
disruption of disulfide linkages by mutagenesis of Cys residues to
Ala or Ser in the human Paneth cell a-defensin HD5 reduced in
vitro bactericidal activity demonstrating the requirement for the
disulfides for in vitro bactericidal activity of this peptide [39]. In
contrast, disruption of disulfide linkages in mouse enteric defensin,
Crp4, by Cys-to-Ala mutagenesis did not eliminate microbicidal
activities of the peptide [40].
Results presented here support the hypothesis that NE and PR3,
proteases that co-localize with myeloid a-defensins, participate in
the intracellular maturation of HNP1. In previous studies with
HL-60 and chronic myelogenous leukemia cells, Valore and Ganz
demonstrated sequential proteolytic processing of proHNP with
the formation of a 56-residue intermediate that is subsequently
processed to mature HNP. While proHNPs were found exclusively
in the cytoplasmic/microsomal fraction, the granule fraction
contained only the intermediate and mature HNP [35]. Therefore
it is likely that proHNP-processing by NE and PR3 occurs during
the packaging of HNPs in azurophil granules. CG processing of
proHNP1A produced a peptide that was extended at the amino
terminus by two residues (Asn-Met) expressed at the carboxyl
terminus of the HNP1 prosegment. Harwig et al. identified a minor
form of HNP3 in fully differentiated neutrophils with the same
Asn-Met dipeptide extension [41] reported here. Thus, CG
processing of proHNP1 may also occur in vivo.
In contrast to the processing of folded proHNP1 by the
azurophilic proteases, misfolded His6-proHNP1 was degraded by
these enzymes. These results are consistent with studies demon-
strating that Cys substitutions in mutants of RMAD4 [32], Crp4
[40] and HD5 [39] are protease sensitive compared to the
respective native peptides. However, in contrast to the examples
cited above, misfolded His6-proHNP1B was disulfide-linked but
still susceptible to proteolysis. These data demonstrate that the
native disulfide motif is essential for proteolytic stability of the
proHNP1 as well as the mature peptide.
Wilson et al. demonstrated that proHNP1 could be processed by
matrix metalloproteinase 7 (MMP7; matrilysin) to generate a 59-
residue molecule with microbicidal activity, but no mature HNP1
(30 amino acids) was detected [42]. Since MMP7 is not present in
neutrophils, it was proposed that MMP7 may be involved in the
extracellular processing of proHNP1 released from the specific
granules of neutrophils. In this regard, Borregaard and co-workers
showed that proHNP1 is present in the specific granules of mature
human neutrophils and that the propeptide is secreted by activated
cells [43]. Since enzymatically active NE is present in inflamma-
tory exudates [44], we hypothesize that proHNP1, elaborated by
activated PMNs, may be activated by NE (and possibly other
enzymes such as PR3 and CG) in the extracellular milieu.
Therefore this process may regulate the extracellular expression of
mature a-defensin in the setting of inflammation.
Materials and Methods
Expression and Purification of His6-proHNP1
The proHNP1 cDNA sequence encoding the natural 75 amino acid
residue sequence extended by 5 amino acids (DDDDK; enterokinase
recognition site) at the N-terminus was amplified using oligonucleotides
(59-GCGAATTCGATGACGATGACAAGGAGCCACTCCAGG-
CAAGAGCTG) and (59-GCGGATCCGGTACCTCGAGTCAG-
CAGCAGAATGCCCAGAGTC) with plasmid PEC2081 (proHNP1
cloned in pCR2.1 Topo vector) as template. EcoRI- and XhoI-digested
DNA was ligated into pET28a+ vector to generate plasmid PEC2129
which encodes proHNP1 with a 41 amino acid residue N-terminal
sequence containing the His6-tag (His6-proHNP1; Fig. 1). The plasmid
was used to transform Escherichia coli BL21(DE3)(codon+), generating
strain PEC2132-1 which was used for expression and purification of
His6-proHNP1.
PEC2132-1 cells were cultured for 3 h at 37uCi n3 Lo f
LB+Kanamycin (50 mg/ml) medium and expression of His6-
proHNP1 was induced by addition of 0.5 mM isopropyl b-D-1-
thiogalactopyranoside (IPTG) for an additional 3 h. Cells were
harvested by centrifugation and lysed by stirring in 60 ml
guanidine lysis buffer (10 mM Tris HCl, 6 M guanidine,
100 mM NaH2PO4, pH 8.0) at room temperature for 2 h. The
lysate was clarified by centrifugation and supernatant was mixed
with 6 ml of Ni-resin (His-Bind resin; Novagen) overnight at 4uC.
Resin was transferred to a chromatography column, washed with
10 volumes of wash buffer 2 (20 mM Tris HCl, 450 mM NaCl,
0.1% Tween, pH 8.0), and bound proteins were eluted with 3.5
column volumes of elution buffer (20 mM Tris-HCl, 450 mM
NaCl, 0.1% Tween, 250 mM imidazole, pH 8.0). The eluate was
dialyzed in Spectrapor 3 membrane against 2 L of dialysis buffer
(4 M guanidine, 20 mM Tris, pH 8.0), overnight at 4uC.
The dialysate was acidified by addition of acetic acid to 10%
(vol/vol) and fractionated on a 10 mm6250 mm Vydac C18
reversed phase high performance liquid chromatography (RP-
HPLC) column equilibrated in aqueous 0.1% trifluoroacetic acid
(TFA). Proteins were eluted using a water-acetonitrile (ACN)
gradient containing 0.1% TFA. As discussed in Results, His6-
Figure 4. Staphylocidal activity of HNP1 generated by CNBr
cleavage of His6-proHNP1. Microbicidal activity of native HNP1 (N)
or HNP1-peptides generated by CNBr-cleavage of His6-proHNP1A (m)
and His6-proHNP1B (¤) was determined in a standard bactericidal
assay against S. aureus 502a.
doi:10.1371/journal.pone.0032469.g004
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retention times of ,35 min and 39 min, respectively. Fractions
corresponding to Peaks A and B were pooled separately and
further purified by C18 RP-HPLC.
Polyacrylamide gel electrophoresis (PAGE) and western
blot analysis
Protein preparations, quantified using the BioRad protein assay
(BSA standard) or by measuring absorbance at 280 nm, were
analyzed by sodium dodecyl sulfate (SDS)-tricine and acid-urea
(AU) gel polyacrylamide gel electrophoresis (PAGE) as described
[45]. For western blotting, proteins resolved by SDS-tricine PAGE
were transferred to nitrocellulose membranes using a GE
Novablot/Pharmacia Biotech Multiphor II system. The mem-
brane was blocked with 5% milk in TTBS (100 mM Tris HCl
pH 7.5, 0.9% NaCl, 0.1% Tween 20) and incubated with
0.02 mg/ml anti-His6 mouse IgG (Qiagen). The membrane was
washed with TTBS and probed with goat anti-Fc mouse IgG-
horse radish peroxidase conjugate (1:20,000 dilution; Sigma) for
1 h, washed with TTBS, and developed by incubation with
Supersignal West Pico chemiluminescent substrate (Pierce) and the
resulting chemiluminesence was visualized on x-ray film.
Mass Spectrometry
Matrix assisted laser desorption/ionization time-of-flight mass
spectroscopy (MALDI-TOF MS) was employed for analysis of
HPLC-purified peptides. Typically, a 0.8 ml sample was mixed 1:1
with sample matrix (15% w/v a-cyano-4-hydroxycinnamic acid
Figure 5. Proteolytic processing of His6-proHNP1 by azurophil granule serine proteases. A) His6-proHNP1A was digested with NE, PR3
and CG as described in Methods and resolved by C18 RP-HPLC. Peptides with masses matching that of HNP1 (asterisks) were identified by MALDI-
TOF-MS. B) Analytical C18 RP-HPLC using the Alliance system of HNP1 isoforms derived from NE, PR3, and CG compared with native HNP1. C) AU-
PAGE followed by Coomassie staining of native HNP1 (lanes 1 and 5) and HNP1 generated by processing with NE (lane 2), PR3 (lane 3) and CG (lane 4).
D) The sequences of mature HNP1 and RMAD4 (underlined) and residues at the junction of their corresponding pro-segment are shown. ProHNP1
and proRMAD4 processing sites mediated by NE, PR3 and CG are indicated.
doi:10.1371/journal.pone.0032469.g005
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MALDI-TOF MS sample plate. In some cases, samples were first
purified using C18 Zip Tips (Millipore) as recommended by the
manufacturer. MALDI-TOF MS was performed on a Microflex
LRF MALDI-TOF system (Bruker Daltonics) [46].
CNBr Cleavage of His6-proHNP1
Samples of lyophilized His6-proHNP1A (150 mg) or His6-
proHNP1B (550 mg) were dissolved in 2 ml 80% formic acid
containing 20 mg CNBr. The reaction mixtures were sparged with
N2 and incubated for 18 h in the dark at room temperature after
which the solutions were diluted 10-fold with water and
lyophilized. The reaction products were dissolved in 0.1% acetic
acid and purified by RP-HPLC on an analytical C18 column and
analyzed by MALDI-TOF MS. Fractions containing HNP1 were
purified further by C18 RP-HPLC.
Enzymatic treatment of proHNP1
Human NE, PR3, and CG were purchased from Elastin Products
Company. Reactions were performed in 50 ml volumes containing
15 mgH i s 6-proHNP1 and 2 mg of protease. Buffer for NE and PR3
reactions was 50 mM Tris-HCl pH 7.5, 150 mM NaCl and CG
reactions were performed in 50 mM Tris-HCl pH 8.3, 150 mM
NaCl [32]. Incubation was performed at 37uC for 18 h after which
5 ml samples were acidified by addition of 10 ml 5% acetic acid, and
desalted with C18 Zip Tips (see above) prior to MALDI-TOF MS
analysis. The remainder of the reaction mixture was subjected to
further purification by RP-HPLC on an analytical C18 column using
a 0–60% water-ACN gradient containing 0.1% TFA. The identity of
putative HNP-containing species was confirmed by MALDI-TOF
MSanalysisof reduced (DTT) and alkylated (iodoacetamide) samples
which produced a new species with the mass of hexa-S-carbox-
yamidomethylated peptide derivative (+348 amu) [47].
To generate enzymatically-processed HNP1 for functional
studies, 150 mg of His6-proHNP1A was digested with 0.1 mg/ml
PR3 or CG in 200 ml or with NE in 400 ml reactions for 22 h at
37uC and purified by C18 RP-HPLC as described above.
Analytical HPLC
HNP1 preparations derived by enzymatic or CNBr treatment were
analyzed on an Alliance 2690 Separations Module using a C18 column
(3 mm particle, 180 A ˚ pore, 2.0 mm6150 mm, Varian Polaris 5A)
with a flow rate of 0.2 ml/min using a 0-to-60% ACN linear gradient
in 0.1% aqueous TFA at 1% per minute. Eluting peaks were detected
at 210 nm and 280 nm using a Waters 2487 Dual l absorbance
detector using Clarity software. Natural (human neutrophil-derived)
HNP1 was used as standard in these analyses.
Microbicidal assays
The antibacterial activity of HNP1 preparations was evaluated
using Staphylococcus aureus 502a as the test organism employing a
microbicidal assay format described previously [46]. Briefly, log
phase cultures of S. aureus (,1610
4 CFU/ml) were suspended in
100 ml buffer (20 mM Tris pH 8.0, 28 mM NaCl) plus 0.03%
TSB with dilutions of HNP1 ranging from 0 to 8 mg/ml in 0.01%
acetic acid for 2 h at 37uC. Aliquots were plated on TSB plates
and colonies were counted after overnight incubation at 37uC.
Native HNP1 from human leukocytes was used as control. The
source of human leukocytes was discarded, de-identified buffy coat
preparations from The University of California Irvine-Medical
Center clinical labs.
Supporting Information
Figure S1 Folding of His6-proHNP1B. His6-proHNP1A and
His6-proHNP1B were analyzed by C18 RP-HPLC and AU-
PAGE. Shown are chromatograms and corresponding Coomassie
stained gels of His6-proHNP1A and His6-proHNP1B analyzed A)
without additional treatment, B) after 4 h incubation in TUN
buffer alone, and C) after 4 h incubation in TUN buffer
supplemented with reduced and oxidized glutathione.
(TIF)
Text S1 Folding of His6-proHNP1B in redox buffer
system. In a previous study, Wu et al. demonstrated efficient
folding of proHNP1 in vitro using reduced/oxidized glutathione to
mediate thiol-disulfide exchange [29]. Employing this approach,
10 mg of HPLC purified His6-proHNP1 was dissolved in 500 ml
50 mM Tris HCl pH 7.5, 0.8 M urea and 100 mM NaCl (TUN
buffer) with or without 2 mM reduced and 0.4 mM oxidized
glutathione and incubated at 37uC for 4 h at which point the
reaction was stopped by addition of 50 ml acetic acid. Reaction
Table 1. Mass spectroscopic analysis of folded and reduced/
alkylated HNP1
a.
Folded S-CAM-derivative Mass gain
Native HNP1 3439.9 [3439.5] 3787.8 [3788.7] 347.9 [348]
NE-derived HNP1 3440.6 [3439.5] 3789.7 [3788.7] 349.1 [348]
PR3-derived HNP1 3441.3 [3439.5] 3789.0 [3788.7] 347.7 [348]
CG- derived HNP1
b 3685.4 [3685.6] 4033.3 [4033.8] 347.9 [348]
aMasses of natural and protease-derived HNP1 preparations were determined
by MALDI-TOF MS before (Folded) and after reduction and S-
carboxamidomethylation (S-CAM-derivative), and the observed gain in mass of
the S-CAM product was calculated. All values shown are shown as atomic mass
units (A.M.U.) of monoisotopic species; theoretical values are in brackets.
bmass of (Asn-Met)-HNP1.
doi:10.1371/journal.pone.0032469.t001
Figure 6. Microbicidal activity of HNP-peptides generated by
NE, PR3 and CG processing of pro-HNP1. Bactericidal activity of
HNP1 isoforms generated by processing with NE (&), PR3 (m), and CG
(¤), with native HNP1 (N) was determined using S. aureus 502a as
described in Methods.
doi:10.1371/journal.pone.0032469.g006
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32469products were purified by RP-HPLC on a Vydac analytical C18
column (4.6 mm6250 mm) using a 20-to-55% (1% per min;
1 ml/min flow rate) linear gradient of ACN in 0.1% TFA
acetonitrile. Peak fractions were collected and analyzed by AU-
PAGE. In the absence of glutathione, the retention time during
RP-HPLC and electrophoretic pattern was unchanged compared
to the respective starting materials (Fig. S1A and B). After
incubation with glutathione, the behavior of proHNP1A was
unchanged on C18 RP-HPLC (Fig. S1C) and on AU PAGE (Fig.
S1C, lane 5). However, treatment of proHNP1B with glutathione
generated a new species that behaved like proHNP1A on both
C18 RP-HPLC and AU-PAGE (Fig. S1C). These data indicate
that proHNP1A and proHNP1B are folded and misfolded forms
of His6-proHNP1respectively and that proHNP1B can be folded
in the presence of reduced/oxidized glutathione.
(DOC)
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